Although feast and famine cycles illustrate that remodelling of adipose tissue in response to fluctuations in nutrient availability is essential for maintaining metabolic homeostasis, the underlying mechanisms remain poorly understood 1,2 . Here we identify fibroblast growth factor 1 (FGF1) as a critical transducer in this process in mice, and link its regulation to the nuclear receptor PPARc (peroxisome proliferator activated receptor c), which is the adipocyte master regulator and the target of the thiazolidinedione class of insulin sensitizing drugs 3-5 . FGF1 is the prototype of the 22member FGF family of proteins and has been implicated in a range of physiological processes, including development, wound healing and cardiovascular changes 6 . Surprisingly, FGF1 knockout mice display no significant phenotype under standard laboratory conditions 7-9 . We show that FGF1 is highly induced in adipose tissue in response to a high-fat diet and that mice lacking FGF1 develop an aggressive diabetic phenotype coupled to aberrant adipose expansion when challenged with a high-fat diet. Further analysis of adipose depots in FGF1-deficient mice revealed multiple histopathologies in the vasculature network, an accentuated inflammatory response, aberrant adipocyte size distribution and ectopic expression of pancreatic lipases. On withdrawal of the high-fat diet, this inflamed adipose tissue fails to properly resolve, resulting in extensive fat necrosis. In terms of mechanisms, we show that adipose induction of FGF1 in the fed state is regulated by PPARc acting through an evolutionarily conserved promoter proximal PPAR response element within the FGF1 gene. The discovery of a phenotype for the FGF1 knockout mouse establishes the PPARc-FGF1 axis as critical for maintaining metabolic homeostasis and insulin sensitization.
Although feast and famine cycles illustrate that remodelling of adipose tissue in response to fluctuations in nutrient availability is essential for maintaining metabolic homeostasis, the underlying mechanisms remain poorly understood 1, 2 . Here we identify fibroblast growth factor 1 (FGF1) as a critical transducer in this process in mice, and link its regulation to the nuclear receptor PPARc (peroxisome proliferator activated receptor c), which is the adipocyte master regulator and the target of the thiazolidinedione class of insulin sensitizing drugs [3] [4] [5] . FGF1 is the prototype of the 22member FGF family of proteins and has been implicated in a range of physiological processes, including development, wound healing and cardiovascular changes 6 . Surprisingly, FGF1 knockout mice display no significant phenotype under standard laboratory conditions [7] [8] [9] . We show that FGF1 is highly induced in adipose tissue in response to a high-fat diet and that mice lacking FGF1 develop an aggressive diabetic phenotype coupled to aberrant adipose expansion when challenged with a high-fat diet. Further analysis of adipose depots in FGF1-deficient mice revealed multiple histopathologies in the vasculature network, an accentuated inflammatory response, aberrant adipocyte size distribution and ectopic expression of pancreatic lipases. On withdrawal of the high-fat diet, this inflamed adipose tissue fails to properly resolve, resulting in extensive fat necrosis. In terms of mechanisms, we show that adipose induction of FGF1 in the fed state is regulated by PPARc acting through an evolutionarily conserved promoter proximal PPAR response element within the FGF1 gene. The discovery of a phenotype for the FGF1 knockout mouse establishes the PPARc-FGF1 axis as critical for maintaining metabolic homeostasis and insulin sensitization.
As part of a directed screen to identify genes that respond to dietary cues in metabolic tissues (muscle, liver, brown adipose tissue (BAT) and white adipose tissue (WAT)), we observed that FGF1 is selectively induced in visceral (that is, gonadal) WAT (gWAT) in response to a high-fat diet (HFD), pointing to a possible metabolic function ( Fig. 1a and Supplementary Fig. 1a, b ). Subfractionation of adipose depots revealed that FGF1 was expressed in the adipocyte fraction but not in the stromal vascular fraction (SVF) of gWAT, and to a lesser extent in the adipocyte fraction of subcutaneous (that is, inguinal) WAT (iWAT) ( Fig. 1b) . Given that FGF1 gene transcription is directed by at least three distinct promoters that are conserved across mammals 10 ( Fig. 1c ), we examined the tissue-specific expression patterns of the alternative splice variants, which differ only in their 59 untranslated exons. Whereas the Fgf1a and Fgf1b splice variants were both expressed in gWAT (as well as other tissues) of mice fed a standard chow diet ( Fig. 1d-f ), only the Fgf1a transcript showed a striking and progressive 20-fold induction between fasted, fed and HFD exposure ( Fig. 1g, h) . Although no metabolic role has been attributed to FGF1, these results prompted us to reconsider this possibility. Consistent with previous reports, no metabolic or histological abnormalities, or major gene expression changes were observed in Fgf1 -/mice fed a standard chow diet 7 Fgf1b Fgf1d
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Fgf1a in gWAT Fgf1b in gWAT showed equivalent changes in weight (monitored for 24 weeks), serum adipokines, cytokines (leptin, resistin, interleukin-6 (IL-6), TNFa, tPAI-1, total and high-molecular-weight adiponectin) and serum lipids (cholesterol, free fatty acids and triglycerides) ( Fig. 1i , Supplementary Tables 1 and 2 ). However, Fgf1 -/mice developed an exaggerated diabetic phenotype, with increased levels of fasting glucose and insulin ( Fig. 2a ), accompanied by severe insulin resistance (Fig. 2b , c) and markedly enhanced serum MCP1/CCL2 (48.0 6 3.4 pg ml 21 compared to 59.0 6 3.4 pg ml 21 , P , 0.01, in wild-type and Fgf1 -/mice, respectively), a marker of adipose macrophage infiltration and a causative factor for peripheral insulin resistance 11, 12 .
To further investigate the role of FGF1 in insulin sensitivity, we performed hyperinsulinaemic-euglycaemic clamp studies. The steady-state glucose infusion rate (GIR) during the clamp was about 40% lower in HFD-fed Fgf1 -/mice, reflecting decreased insulin responsiveness, and was accompanied by reductions in whole-body and insulin-stimulated glucose disposal rates (GDR and IS-GDR), indicating pronounced peripheral insulin resistance ( Fig. 2d-f ). The ability of insulin to suppress hepatic glucose production (HGP) was also significantly compromised in HFD-fed Fgf1 -/mice, revealing hepatic insulin resistance as well ( Fig. 2g ). Although HFD-fed Fgf1 -/mice had enlarged steatotic livers relative to wild-type controls ( Fig. 2h , i), liver function (based on serum alanine transaminase (ALT) levels) and pancreatic function (based on islet histology and insulin secretion) appeared normal ( Supplementary Fig. 3, 4 ). On the other hand, gWAT in Fgf1 2/2 mice failed to expand after HFD and exhibited pronounced structural abnormalities, as evidenced by haematoxylin and eosin staining ( Fig. 2j , k, Supplementary Fig. 5 ). As expected with higher circulating levels of MCP1, we observed a dramatic increase in macrophage infiltration, indicating a highly inflamed gWAT ( Fig. 3a) . Notably, no defects were observed in iWAT (data not shown). This differential sensitivity of WAT depots to HFD stress is consistent with the known association of the visceral WAT with obesity-related pathologies including insulin resistance 13 .
To explore the possibility that the metabolic dysregulation observed in Fgf1 -/mice on an HFD was associated with defects in gWAT, we performed detailed histological and molecular analyses of this tissue. Histochemistry with Masson's trichrome stain of gWAT from the HFD-fed Fgf1 -/mice revealed increased collagen deposition (blue staining) and a marked heterogeneity in adipocyte size (Fig. 3b ). Quantification of adipocyte cross-sectional areas showed increases in the numbers of both small and large adipocytes in Fgf1 -/mice relative to wild-type ( Fig. 3c ). Next we examined the functional architecture of the adipose vasculature by intravenous injection of fluorescent microbeads. Epifluorescence microscopy of tissue sections from fluorescent-bead-perfused mice revealed decreased vascular density specifically in gWAT ( Fig. 3d ) but not in BAT or iWAT of HFD-fed Fgf1 -/mice ( Supplementary Fig. 6 ). Microarray analyses identified multiple transcriptional changes induced by HFD in Fgf1 -/-gWAT that were consistent with the observed phenotypes. The obesity and insulin resistance markers RBP4 and CCL11 were upregulated by 
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HFD, as was the angiogenic factor VEGF. Interestingly, expression of PPARc was also induced by HFD in Fgf1 -/-gWAT, as was the expression of known PPARc target genes (for example, perilipin, Dgat1 and Dgat2) ( Supplementary Table 3 ). However, the most dramatic inductions of gene expression were seen in multiple fat necrosis-associated pancreatic lipases and the tissue remodelling factor elastase 1, which were confirmed by quantitative polymerase chain reaction (qPCR; Fig. 3e , Supplementary Table 3 ) [14] [15] [16] .
The observed histopathological and molecular changes in Fgf1 -/-gWAT suggested a failure to execute the appropriate adipose remodelling program in response to HFD stress. As adipose tissue needs to dynamically expand and contract with fluctuations in nutrient availability, we postulated that FGF1 would also play a role in its contraction capacity on withdrawal from HFD. To test this, we readapted HFD-fed wild-type and Fgf1 -/mice to 6 weeks of chow feeding. Gross examination of HFD-to-chow converted (HCC) mice revealed features consistent with maladaptation resulting in disfigurement and discoloration of gWAT from Fgf1 -/mice compared to control wild-type mice (Fig. 3f ). Histological examination of the HCC Fgf1 -/-gWAT showed profound degeneration of adipose architecture and integrity of far greater severity than the HCC wild-type gWAT (Fig. 3g ). Indeed, HCC Fgf1 -/mice frequently presented with what appeared to be fragments of dissociated fat tissue within the peritoneal cavity, which upon histological analysis were consistent with a fat necrosis pathology (Fig. 3h ). The observations from the HFD and HCC regimens demonstrate a dynamic requirement for FGF1 in both adipose tissue expansion and contraction. Together, our findings show that when challenged with an HFD or HCC, Fgf1 -/mice are unable to remodel visceral adipose tissue in response to dietary changes. This suggests that defects in adipose plasticity, attributable to the loss of FGF1, are causally linked with a series of peripheral pathologies, including hepatic steatosis and systemic insulin resistance. These results establish FGF1 as a transducer of adipose remodelling in response to nutrient fluctuations, and identify an indispensible role for FGF1 in defending the body against metabolic disease.
As PPARc expression was induced in Fgf1 -/-gWAT by HFD, and HFD elevates the levels of circulating PPAR ligands 17, 18 , we postulated that the HFD-induction of the Fgf1a splice variant may be regulated by a PPAR family member. Luciferase reporter assays indeed revealed a robust induction of the human FGF1A transcript by the PPARs, of which PPARc was the most potent ( Fig. 4a ). Furthermore, in this system the PPAR induction of FGF1 appears specific to the FGF1A transcript, as PPARs did not induce expression of the FGF1B splice variant (Fig. 4b) . Examination of the promoter region of the FGF1A transcript revealed a highly conserved (98% conservation) region ,100 base pairs (bp) proximal to the transcription start site ( Supplementary Fig. 7a ) containing a conserved putative PPAR response element (PPRE) at 260 bp relative to the transcription start site (Fig. 4c ). Inactivation of this PPRE using site directed mutagenesis resulted in a complete loss of its response to PPARc (Fig. 4c, d : compare human versus DPPRE). To examine the functional conservation of FGF1 regulation by PPARc, we assayed the native human and mouse FGF1A promoters along with reporter constructs containing orthologous PPREs (rat, horse and opossum) introduced into the human FGF1A promoter. PPARc activation was observed for all promoters except for the more distantly related opossum PPRE (Fig. 4d ). Chromatin immunoprecipitation (ChIP) experiments confirmed that PPARc does indeed bind to the identified PPRE in 3T3-L1 adipocytes (Fig. 4e, Supplementary Fig. 7b ). Data mining of a published genome-wide PPARc ChIP sequencing (ChIP-Seq) study indicates that the PPARc-Fgf1a promoter interaction may be specific to the adipocyte fraction within WAT, as PPARc binding was seen in 3T3-L1 adipocytes, but not in macrophages 19 . Together, these findings show that the adipocyte PPARc-FGF1 axis is functionally conserved in a wide range of mammals.
To confirm the physiological relevance of the PPARc induction of FGF1, we determined the expression of the Fgf1A transcript in mice in response to the potent and specific PPARc ligand rosiglitazone. We found that oral administration of rosiglitazone (5 mg kg 21 for 3 days) significantly increased the levels of the Fgf1a transcript in gWAT, in fed but not fasted states (Fig. 4f ). The expression of Fgf1b and Fgf1d transcripts was unchanged by rosiglitazone in gWAT and liver ( Fig. 4g ; LETTER RESEARCH Supplementary Fig. 8 ), whereas Fgf1a and Fgf1d transcripts were undetectable in liver and gWAT, respectively (data not shown). Furthermore, adipocyte-specific PPARc knockout mice 20 displayed decreased levels of FGF1 in the adipocyte fraction, without compensatory changes in the closely related FGF2, which was only detected in the SVF (Fig. 4h) .
We have discovered an unexpected metabolic role for FGF1 as a critical transducer of PPARc signalling that mediates the proper coupling of nutrient storage to adaptive remodelling of adipose tissue. We found that HFD results in potent and selective induction of FGF1 in adipose tissue and that its transcription is controlled by PPARc and its insulin sensitizing ligands. Loss of FGF1 leads to systemic metabolic dysfunction and insulin resistance, revealing an indispensable role for FGF1 in metabolic homeostasis (Fig. 4i) . Importantly, we show that Fgf1 -/mice are unable to both properly expand and contract their adipose tissue in response to dietary changes, revealing the dynamic requirement of FGF1 for adipose tissue remodelling. The capacity of adipose tissue to remodel is crucial for accommodating changes in energy availability in fasted and fed states but is not unlimited, and can become perturbed in obesity and related pathologies. Previous reports have shown that FGF1 can signal through FGFRs to pre-adipocytes [21] [22] [23] . Recently, several endocrine FGF family members (FGF15/19, 21) have been linked to metabolic homeostasis through nuclear receptor regulation [24] [25] [26] . We now expand this nuclear receptor-FGF interface to include the paracrine FGF1. Our discovery of the PPARc-FGF1 axis leads us to consider the therapeutic potential of FGF1 in potentially mediating insulin sensitization without provoking the full range of adverse events associated with PPARc activation.
METHODS SUMMARY
Fgf1 -/mice and age-and sex-matched wild-type controls (.99% C57BL/6 genetic background) received a standard diet or high fat (60%) diet (F3282, Bio-Serv) and water ad libitum. For the HFD-to-chow conversion diet regimen (HCC), mice were fed HFD starting from 6 weeks of age. After 9 months of HFD, the diet was converted back to standard laboratory chow for 6 weeks. Glucose tolerance tests and insulin tolerance tests were conducted after overnight fasting and after 5 h fasting, respectively. Glucose (1 g per kg, i.p.) or insulin (0.5 U insulin per kg, i.p.) was injected and blood glucose monitored. Serum analyses were performed on blood collected by tail bleeding either in the ad libitum fed state or following overnight fasting. Free fatty acids, triglycerides, cholesterol and ALT were measured using commercial enzymatic colorimetric kits. Serum insulin levels and total and high-molecular weight (HMW) adiponectin levels were measured by ELISAs using commercial kits. Plasma adipokine levels were measured using a Milliplex MAP kit. Histological and immunohistochemical analyses were performed on sections of fixed tissues according to standard procedures.
Vasculature was visualized by tail vein injection of fluorescent microbeads (0.1 mm FluoSpheres, Molecular Probes). Subsequently, mice were anaesthetized and perfused through the heart with additional fluorescent microbeads. Tissues were dissected, embedded and 10-mm frozen sections analysed for blood vessel density using fluorescence microscopy.
Luciferase reporter assays were performed in CV-1 cells treated overnight with or without ligands (PPARa, 1 mM WY14643 (Cayman Chemicals); PPARc, 1 mM rosiglitazone (TZD) (Cayman Chemicals); PPARd, 100 nM GW1516 (Santa Cruz)). Site-directed mutagenesis of the PPRE in the human FGF1A promoter was performed using a QuikChange II kit.
Chromatin immunoprecipitation assays were performed on differentiated 3T3-L1 cells. Sheared chromatin generated from cross-linked cell pellets by sonication was incubated with PPARc antibody or control rabbit IgG, and precipitated with pre-blocked protein A-agarose beads.
